Bruker Corporation

Bruker Corporation(BRKR)の株式分析

$55.370

+0.576 (+1.04%)終値時点

Loading chart…
高値
56.200
始値
54.890
出来高加重平均価格
55.42
出来高
1.91M
時価総額
9.72B
安値
54.680
売買代金
105.95M
EV/EBITDA(TTM)
16.91

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others.

www.bruker.com

AI分析 of Bruker Corporation (BRKR)

中立

Bruker Corp is currently trading at $54.80, which is below several analyst price targets, including $70 from Barclays and $72 from Guggenheim, indicating potential upside. However, the stock has a low RSI of 26.87, suggesting it is oversold, and a negative 5-day change of -6.87% indicates recent weakness. The main risk is the significant net income loss of $62.9 million reported in Q2 2026, which raises concerns about profitability.

アナリスト評価(14)

-5.76% 下落余地
中立
2 買い
10 中立
2 売り
現在: 55.37
安値
40.00
平均
52.18
高値
60.00

Barclays

2026-10-07

目標株価

$70

オーバーウェイト

Guggenheim

2026-10-01

目標株価

$72

買い

Leerink

2026-09-29

目標株価

$80

アウトパフォーム

UBS

2026-09-09

目標株価

$65

中立

TD Cowen

2026-07-15

目標株価

$60

中立

バリュエーション指標

Bruker Corporation(BRKR)の現在の予想PERは13.83で、5年平均は23.47です。

予想PER

割安
5年平均 P/E
23.47
現在のP/E
13.83
割高
29.56
割安
17.38

予想EV/EBITDA

適正
5年平均 EV/EBITDA
17.55
現在のEV/EBITDA
16.91
割高
21.12
割安
13.98

予想PSR

適正
5年平均 P/S
2.90
現在のP/S
2.25
割高
3.81
割安
1.99

Alphio AI による BRKR の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%BRKR

$53.26

シナリオ価格

基

基本

基本 · 50%BRKR

$44.40

シナリオ価格

弱

弱気

弱気 · 25%BRKR

$41.00

シナリオ価格

BRKR を保有するクジラ

B

Becker Capital Management Inc

+ を保有BRKR

+4.10%

3か月リターン

S

Steadfast Capital Management LP

+ を保有BRKR

+1.78%

3か月リターン

C

Cornerstone Investment Partners, LLC

+ を保有BRKR

+1.13%

3か月リターン

E

Eversept Partners, L.P.

+ を保有BRKR

-9.17%

3か月リターン

BRKR のよくある質問 — Alphio AI が回答

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Bruker Corp is currently trading at $54.80, which is below several analyst price targets, including $70 from Barclays and $72 from Guggenheim, indicating potential upside. However, the stock has a low RSI of 26.87, suggesting it is oversold, and a negative 5-day change of -6.87% indicates recent weakness. The main risk is the significant net income loss of $62.9 million reported in Q2 2026, which raises concerns about profitability.

14 analysts cover BRKR: 2 rate it Buy, 10 Hold and 2 Sell. The average price target is 52.18.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める